Global AI for Pharma and Biotech
Global AI for Pharma and Biotech

AI for Pharma and Biotech Comprehensive Study by Type (Deep Learning, Big Data, Image Detection), Application (Hospital, Clinic, Research Center, Academic & Government Institutes, Others), End Use (Drug discovery, Clinical research, Disease diagnosis, Novel medication, Prediction, Data analysis, Other), Component (Software, Services) Players and Region - Global Market Outlook to 2026

AI for Pharma and Biotech Market Segmented into XX Submarkets. | Forecast Years: 2021- 2026  

Dec 2021 Edition 211 Pages 211 Tables & Figures
  • Summary
  • Market Segments
  • Table of Content
  • List of Tables & Figures
  • Companies Mentioned
The Global AI for Pharma and Biotech market presents a comprehensive analysis of the AI for Pharma and Biotech market by product type (Deep Learning, Big Data and Image Detection), by end-user/application (Hospital, Clinic, Research Center, Academic & Government Institutes and Others), and by geography (North America, South America, Europe, Asia-Pacific and MEA) along with country level break-up.

Market Snapshot:
In the pharmaceutical sector, artificial intelligence (AI) refers to a system of interconnected and automated technologies that can function independently with little or no human interaction. AI is a new technology that is being used in the pharmaceutical industry in a variety of ways, from drug development to diagnostics and even patient care. By enhancing candidate screening processes for clinical trials, AI will also affect the future of pharmaceuticals. AI can help ensure trial adoption by instantly evaluating patients and determining the best prospects for a given trial.

Market Drivers
  • Increasing Clinical Trials

Market Trend
  • Growing Digitization In Pharma Industry

Restraints
  • High Cost Associated To AI Technology


Geographic Segmentation and Analysis
This section of our report presents a realistic picture of the Global AI for Pharma and Biotech industry. Investors and manufacturers can easily understand the inherent opportunities and challenges for their products in geographical region of interest.
The regional segmentation covered in this report are:
South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico)

Frequently Asked Questions (FAQ):

1. Why many important players are not profiled in the study?
Due to pricing constraints we only profile limited players in the study that includes a mix list of leaders and emerging players, however for evaluation of market size the coverage includes 100+ players.

2. How big is the AI for Pharma and Biotech Market?
Yes, the study does represent market size by key business segment, application/end users and major geographies forecasted till 2026

3. Is it possible to have certain customization in the study?
The Study can be customized to meet your requirements. Please connect with our representative, in case you wish to add or remove certain country or profiled players.
Report Objectives / Segmentation Covered
By Type
  • Deep Learning
  • Big Data
  • Image Detection
By Application
  • Hospital
  • Clinic
  • Research Center
  • Academic & Government Institutes
  • Others
By End Use
  • Drug discovery
  • Clinical research
  • Disease diagnosis
  • Novel medication
  • Prediction
  • Data analysis
  • Other

By Component
  • Software
  • Services

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increasing Clinical Trials
    • 3.3. Market Challenges
      • 3.3.1. Lack Of Skill Professionals
      • 3.3.2. AI Technology Isn't Completely Error-Free
    • 3.4. Market Trends
      • 3.4.1. Growing Digitization In Pharma Industry
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global AI for Pharma and Biotech, by Type, Application, End Use, Component and Region (value and price ) (2015-2020)
    • 5.1. Introduction
    • 5.2. Global AI for Pharma and Biotech (Value)
      • 5.2.1. Global AI for Pharma and Biotech by: Type (Value)
        • 5.2.1.1. Deep Learning
        • 5.2.1.2. Big Data
        • 5.2.1.3. Image Detection
      • 5.2.2. Global AI for Pharma and Biotech by: Application (Value)
        • 5.2.2.1. Hospital
        • 5.2.2.2. Clinic
        • 5.2.2.3. Research Center
        • 5.2.2.4. Academic & Government Institutes
        • 5.2.2.5. Others
      • 5.2.3. Global AI for Pharma and Biotech by: End Use (Value)
        • 5.2.3.1. Drug discovery
        • 5.2.3.2. Clinical research
        • 5.2.3.3. Disease diagnosis
        • 5.2.3.4. Novel medication
        • 5.2.3.5. Prediction
        • 5.2.3.6. Data analysis
        • 5.2.3.7. Other
      • 5.2.4. Global AI for Pharma and Biotech by: Component (Value)
        • 5.2.4.1. Software
        • 5.2.4.2. Services
      • 5.2.5. Global AI for Pharma and Biotech Region
        • 5.2.5.1. South America
          • 5.2.5.1.1. Brazil
          • 5.2.5.1.2. Argentina
          • 5.2.5.1.3. Rest of South America
        • 5.2.5.2. Asia Pacific
          • 5.2.5.2.1. China
          • 5.2.5.2.2. Japan
          • 5.2.5.2.3. India
          • 5.2.5.2.4. South Korea
          • 5.2.5.2.5. Taiwan
          • 5.2.5.2.6. Australia
          • 5.2.5.2.7. Rest of Asia-Pacific
        • 5.2.5.3. Europe
          • 5.2.5.3.1. Germany
          • 5.2.5.3.2. France
          • 5.2.5.3.3. Italy
          • 5.2.5.3.4. United Kingdom
          • 5.2.5.3.5. Netherlands
          • 5.2.5.3.6. Rest of Europe
        • 5.2.5.4. MEA
          • 5.2.5.4.1. Middle East
          • 5.2.5.4.2. Africa
        • 5.2.5.5. North America
          • 5.2.5.5.1. United States
          • 5.2.5.5.2. Canada
          • 5.2.5.5.3. Mexico
    • 5.3. Global AI for Pharma and Biotech (Price)
      • 5.3.1. Global AI for Pharma and Biotech by: Type (Price)
  • 6. AI for Pharma and Biotech: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2020)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. CureMetrix (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. PFIZER (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Abbott (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. JANSSEN PHARMACEUTICALS (Belgium)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. SANOFI (France)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. NOVARTIS (Switzerland)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. VoxelCloud (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. BAYER (Germany)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Insilico Medicine (Hong Kong)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Oncora Medical (United States)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
      • 6.4.11. Atomwise (United States)
        • 6.4.11.1. Business Overview
        • 6.4.11.2. Products/Services Offerings
        • 6.4.11.3. Financial Analysis
        • 6.4.11.4. SWOT Analysis
  • 7. Global AI for Pharma and Biotech Sale, by Type, Application, End Use, Component and Region (value and price ) (2021-2026)
    • 7.1. Introduction
    • 7.2. Global AI for Pharma and Biotech (Value)
      • 7.2.1. Global AI for Pharma and Biotech by: Type (Value)
        • 7.2.1.1. Deep Learning
        • 7.2.1.2. Big Data
        • 7.2.1.3. Image Detection
      • 7.2.2. Global AI for Pharma and Biotech by: Application (Value)
        • 7.2.2.1. Hospital
        • 7.2.2.2. Clinic
        • 7.2.2.3. Research Center
        • 7.2.2.4. Academic & Government Institutes
        • 7.2.2.5. Others
      • 7.2.3. Global AI for Pharma and Biotech by: End Use (Value)
        • 7.2.3.1. Drug discovery
        • 7.2.3.2. Clinical research
        • 7.2.3.3. Disease diagnosis
        • 7.2.3.4. Novel medication
        • 7.2.3.5. Prediction
        • 7.2.3.6. Data analysis
        • 7.2.3.7. Other
      • 7.2.4. Global AI for Pharma and Biotech by: Component (Value)
        • 7.2.4.1. Software
        • 7.2.4.2. Services
      • 7.2.5. Global AI for Pharma and Biotech Region
        • 7.2.5.1. South America
          • 7.2.5.1.1. Brazil
          • 7.2.5.1.2. Argentina
          • 7.2.5.1.3. Rest of South America
        • 7.2.5.2. Asia Pacific
          • 7.2.5.2.1. China
          • 7.2.5.2.2. Japan
          • 7.2.5.2.3. India
          • 7.2.5.2.4. South Korea
          • 7.2.5.2.5. Taiwan
          • 7.2.5.2.6. Australia
          • 7.2.5.2.7. Rest of Asia-Pacific
        • 7.2.5.3. Europe
          • 7.2.5.3.1. Germany
          • 7.2.5.3.2. France
          • 7.2.5.3.3. Italy
          • 7.2.5.3.4. United Kingdom
          • 7.2.5.3.5. Netherlands
          • 7.2.5.3.6. Rest of Europe
        • 7.2.5.4. MEA
          • 7.2.5.4.1. Middle East
          • 7.2.5.4.2. Africa
        • 7.2.5.5. North America
          • 7.2.5.5.1. United States
          • 7.2.5.5.2. Canada
          • 7.2.5.5.3. Mexico
    • 7.3. Global AI for Pharma and Biotech (Price)
      • 7.3.1. Global AI for Pharma and Biotech by: Type (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. AI for Pharma and Biotech: by Type(USD Million)
  • Table 2. AI for Pharma and Biotech Deep Learning , by Region USD Million (2015-2020)
  • Table 3. AI for Pharma and Biotech Big Data , by Region USD Million (2015-2020)
  • Table 4. AI for Pharma and Biotech Image Detection , by Region USD Million (2015-2020)
  • Table 5. AI for Pharma and Biotech: by Application(USD Million)
  • Table 6. AI for Pharma and Biotech Hospital , by Region USD Million (2015-2020)
  • Table 7. AI for Pharma and Biotech Clinic , by Region USD Million (2015-2020)
  • Table 8. AI for Pharma and Biotech Research Center , by Region USD Million (2015-2020)
  • Table 9. AI for Pharma and Biotech Academic & Government Institutes , by Region USD Million (2015-2020)
  • Table 10. AI for Pharma and Biotech Others , by Region USD Million (2015-2020)
  • Table 11. AI for Pharma and Biotech: by End Use(USD Million)
  • Table 12. AI for Pharma and Biotech Drug discovery , by Region USD Million (2015-2020)
  • Table 13. AI for Pharma and Biotech Clinical research , by Region USD Million (2015-2020)
  • Table 14. AI for Pharma and Biotech Disease diagnosis , by Region USD Million (2015-2020)
  • Table 15. AI for Pharma and Biotech Novel medication , by Region USD Million (2015-2020)
  • Table 16. AI for Pharma and Biotech Prediction , by Region USD Million (2015-2020)
  • Table 17. AI for Pharma and Biotech Data analysis , by Region USD Million (2015-2020)
  • Table 18. AI for Pharma and Biotech Other , by Region USD Million (2015-2020)
  • Table 19. AI for Pharma and Biotech: by Component(USD Million)
  • Table 20. AI for Pharma and Biotech Software , by Region USD Million (2015-2020)
  • Table 21. AI for Pharma and Biotech Services , by Region USD Million (2015-2020)
  • Table 22. South America AI for Pharma and Biotech, by Country USD Million (2015-2020)
  • Table 23. South America AI for Pharma and Biotech, by Type USD Million (2015-2020)
  • Table 24. South America AI for Pharma and Biotech, by Application USD Million (2015-2020)
  • Table 25. South America AI for Pharma and Biotech, by End Use USD Million (2015-2020)
  • Table 26. South America AI for Pharma and Biotech, by Component USD Million (2015-2020)
  • Table 27. Brazil AI for Pharma and Biotech, by Type USD Million (2015-2020)
  • Table 28. Brazil AI for Pharma and Biotech, by Application USD Million (2015-2020)
  • Table 29. Brazil AI for Pharma and Biotech, by End Use USD Million (2015-2020)
  • Table 30. Brazil AI for Pharma and Biotech, by Component USD Million (2015-2020)
  • Table 31. Argentina AI for Pharma and Biotech, by Type USD Million (2015-2020)
  • Table 32. Argentina AI for Pharma and Biotech, by Application USD Million (2015-2020)
  • Table 33. Argentina AI for Pharma and Biotech, by End Use USD Million (2015-2020)
  • Table 34. Argentina AI for Pharma and Biotech, by Component USD Million (2015-2020)
  • Table 35. Rest of South America AI for Pharma and Biotech, by Type USD Million (2015-2020)
  • Table 36. Rest of South America AI for Pharma and Biotech, by Application USD Million (2015-2020)
  • Table 37. Rest of South America AI for Pharma and Biotech, by End Use USD Million (2015-2020)
  • Table 38. Rest of South America AI for Pharma and Biotech, by Component USD Million (2015-2020)
  • Table 39. Asia Pacific AI for Pharma and Biotech, by Country USD Million (2015-2020)
  • Table 40. Asia Pacific AI for Pharma and Biotech, by Type USD Million (2015-2020)
  • Table 41. Asia Pacific AI for Pharma and Biotech, by Application USD Million (2015-2020)
  • Table 42. Asia Pacific AI for Pharma and Biotech, by End Use USD Million (2015-2020)
  • Table 43. Asia Pacific AI for Pharma and Biotech, by Component USD Million (2015-2020)
  • Table 44. China AI for Pharma and Biotech, by Type USD Million (2015-2020)
  • Table 45. China AI for Pharma and Biotech, by Application USD Million (2015-2020)
  • Table 46. China AI for Pharma and Biotech, by End Use USD Million (2015-2020)
  • Table 47. China AI for Pharma and Biotech, by Component USD Million (2015-2020)
  • Table 48. Japan AI for Pharma and Biotech, by Type USD Million (2015-2020)
  • Table 49. Japan AI for Pharma and Biotech, by Application USD Million (2015-2020)
  • Table 50. Japan AI for Pharma and Biotech, by End Use USD Million (2015-2020)
  • Table 51. Japan AI for Pharma and Biotech, by Component USD Million (2015-2020)
  • Table 52. India AI for Pharma and Biotech, by Type USD Million (2015-2020)
  • Table 53. India AI for Pharma and Biotech, by Application USD Million (2015-2020)
  • Table 54. India AI for Pharma and Biotech, by End Use USD Million (2015-2020)
  • Table 55. India AI for Pharma and Biotech, by Component USD Million (2015-2020)
  • Table 56. South Korea AI for Pharma and Biotech, by Type USD Million (2015-2020)
  • Table 57. South Korea AI for Pharma and Biotech, by Application USD Million (2015-2020)
  • Table 58. South Korea AI for Pharma and Biotech, by End Use USD Million (2015-2020)
  • Table 59. South Korea AI for Pharma and Biotech, by Component USD Million (2015-2020)
  • Table 60. Taiwan AI for Pharma and Biotech, by Type USD Million (2015-2020)
  • Table 61. Taiwan AI for Pharma and Biotech, by Application USD Million (2015-2020)
  • Table 62. Taiwan AI for Pharma and Biotech, by End Use USD Million (2015-2020)
  • Table 63. Taiwan AI for Pharma and Biotech, by Component USD Million (2015-2020)
  • Table 64. Australia AI for Pharma and Biotech, by Type USD Million (2015-2020)
  • Table 65. Australia AI for Pharma and Biotech, by Application USD Million (2015-2020)
  • Table 66. Australia AI for Pharma and Biotech, by End Use USD Million (2015-2020)
  • Table 67. Australia AI for Pharma and Biotech, by Component USD Million (2015-2020)
  • Table 68. Rest of Asia-Pacific AI for Pharma and Biotech, by Type USD Million (2015-2020)
  • Table 69. Rest of Asia-Pacific AI for Pharma and Biotech, by Application USD Million (2015-2020)
  • Table 70. Rest of Asia-Pacific AI for Pharma and Biotech, by End Use USD Million (2015-2020)
  • Table 71. Rest of Asia-Pacific AI for Pharma and Biotech, by Component USD Million (2015-2020)
  • Table 72. Europe AI for Pharma and Biotech, by Country USD Million (2015-2020)
  • Table 73. Europe AI for Pharma and Biotech, by Type USD Million (2015-2020)
  • Table 74. Europe AI for Pharma and Biotech, by Application USD Million (2015-2020)
  • Table 75. Europe AI for Pharma and Biotech, by End Use USD Million (2015-2020)
  • Table 76. Europe AI for Pharma and Biotech, by Component USD Million (2015-2020)
  • Table 77. Germany AI for Pharma and Biotech, by Type USD Million (2015-2020)
  • Table 78. Germany AI for Pharma and Biotech, by Application USD Million (2015-2020)
  • Table 79. Germany AI for Pharma and Biotech, by End Use USD Million (2015-2020)
  • Table 80. Germany AI for Pharma and Biotech, by Component USD Million (2015-2020)
  • Table 81. France AI for Pharma and Biotech, by Type USD Million (2015-2020)
  • Table 82. France AI for Pharma and Biotech, by Application USD Million (2015-2020)
  • Table 83. France AI for Pharma and Biotech, by End Use USD Million (2015-2020)
  • Table 84. France AI for Pharma and Biotech, by Component USD Million (2015-2020)
  • Table 85. Italy AI for Pharma and Biotech, by Type USD Million (2015-2020)
  • Table 86. Italy AI for Pharma and Biotech, by Application USD Million (2015-2020)
  • Table 87. Italy AI for Pharma and Biotech, by End Use USD Million (2015-2020)
  • Table 88. Italy AI for Pharma and Biotech, by Component USD Million (2015-2020)
  • Table 89. United Kingdom AI for Pharma and Biotech, by Type USD Million (2015-2020)
  • Table 90. United Kingdom AI for Pharma and Biotech, by Application USD Million (2015-2020)
  • Table 91. United Kingdom AI for Pharma and Biotech, by End Use USD Million (2015-2020)
  • Table 92. United Kingdom AI for Pharma and Biotech, by Component USD Million (2015-2020)
  • Table 93. Netherlands AI for Pharma and Biotech, by Type USD Million (2015-2020)
  • Table 94. Netherlands AI for Pharma and Biotech, by Application USD Million (2015-2020)
  • Table 95. Netherlands AI for Pharma and Biotech, by End Use USD Million (2015-2020)
  • Table 96. Netherlands AI for Pharma and Biotech, by Component USD Million (2015-2020)
  • Table 97. Rest of Europe AI for Pharma and Biotech, by Type USD Million (2015-2020)
  • Table 98. Rest of Europe AI for Pharma and Biotech, by Application USD Million (2015-2020)
  • Table 99. Rest of Europe AI for Pharma and Biotech, by End Use USD Million (2015-2020)
  • Table 100. Rest of Europe AI for Pharma and Biotech, by Component USD Million (2015-2020)
  • Table 101. MEA AI for Pharma and Biotech, by Country USD Million (2015-2020)
  • Table 102. MEA AI for Pharma and Biotech, by Type USD Million (2015-2020)
  • Table 103. MEA AI for Pharma and Biotech, by Application USD Million (2015-2020)
  • Table 104. MEA AI for Pharma and Biotech, by End Use USD Million (2015-2020)
  • Table 105. MEA AI for Pharma and Biotech, by Component USD Million (2015-2020)
  • Table 106. Middle East AI for Pharma and Biotech, by Type USD Million (2015-2020)
  • Table 107. Middle East AI for Pharma and Biotech, by Application USD Million (2015-2020)
  • Table 108. Middle East AI for Pharma and Biotech, by End Use USD Million (2015-2020)
  • Table 109. Middle East AI for Pharma and Biotech, by Component USD Million (2015-2020)
  • Table 110. Africa AI for Pharma and Biotech, by Type USD Million (2015-2020)
  • Table 111. Africa AI for Pharma and Biotech, by Application USD Million (2015-2020)
  • Table 112. Africa AI for Pharma and Biotech, by End Use USD Million (2015-2020)
  • Table 113. Africa AI for Pharma and Biotech, by Component USD Million (2015-2020)
  • Table 114. North America AI for Pharma and Biotech, by Country USD Million (2015-2020)
  • Table 115. North America AI for Pharma and Biotech, by Type USD Million (2015-2020)
  • Table 116. North America AI for Pharma and Biotech, by Application USD Million (2015-2020)
  • Table 117. North America AI for Pharma and Biotech, by End Use USD Million (2015-2020)
  • Table 118. North America AI for Pharma and Biotech, by Component USD Million (2015-2020)
  • Table 119. United States AI for Pharma and Biotech, by Type USD Million (2015-2020)
  • Table 120. United States AI for Pharma and Biotech, by Application USD Million (2015-2020)
  • Table 121. United States AI for Pharma and Biotech, by End Use USD Million (2015-2020)
  • Table 122. United States AI for Pharma and Biotech, by Component USD Million (2015-2020)
  • Table 123. Canada AI for Pharma and Biotech, by Type USD Million (2015-2020)
  • Table 124. Canada AI for Pharma and Biotech, by Application USD Million (2015-2020)
  • Table 125. Canada AI for Pharma and Biotech, by End Use USD Million (2015-2020)
  • Table 126. Canada AI for Pharma and Biotech, by Component USD Million (2015-2020)
  • Table 127. Mexico AI for Pharma and Biotech, by Type USD Million (2015-2020)
  • Table 128. Mexico AI for Pharma and Biotech, by Application USD Million (2015-2020)
  • Table 129. Mexico AI for Pharma and Biotech, by End Use USD Million (2015-2020)
  • Table 130. Mexico AI for Pharma and Biotech, by Component USD Million (2015-2020)
  • Table 131. AI for Pharma and Biotech: by Type(USD/Units)
  • Table 132. Company Basic Information, Sales Area and Its Competitors
  • Table 133. Company Basic Information, Sales Area and Its Competitors
  • Table 134. Company Basic Information, Sales Area and Its Competitors
  • Table 135. Company Basic Information, Sales Area and Its Competitors
  • Table 136. Company Basic Information, Sales Area and Its Competitors
  • Table 137. Company Basic Information, Sales Area and Its Competitors
  • Table 138. Company Basic Information, Sales Area and Its Competitors
  • Table 139. Company Basic Information, Sales Area and Its Competitors
  • Table 140. Company Basic Information, Sales Area and Its Competitors
  • Table 141. Company Basic Information, Sales Area and Its Competitors
  • Table 142. Company Basic Information, Sales Area and Its Competitors
  • Table 143. AI for Pharma and Biotech: by Type(USD Million)
  • Table 144. AI for Pharma and Biotech Deep Learning , by Region USD Million (2021-2026)
  • Table 145. AI for Pharma and Biotech Big Data , by Region USD Million (2021-2026)
  • Table 146. AI for Pharma and Biotech Image Detection , by Region USD Million (2021-2026)
  • Table 147. AI for Pharma and Biotech: by Application(USD Million)
  • Table 148. AI for Pharma and Biotech Hospital , by Region USD Million (2021-2026)
  • Table 149. AI for Pharma and Biotech Clinic , by Region USD Million (2021-2026)
  • Table 150. AI for Pharma and Biotech Research Center , by Region USD Million (2021-2026)
  • Table 151. AI for Pharma and Biotech Academic & Government Institutes , by Region USD Million (2021-2026)
  • Table 152. AI for Pharma and Biotech Others , by Region USD Million (2021-2026)
  • Table 153. AI for Pharma and Biotech: by End Use(USD Million)
  • Table 154. AI for Pharma and Biotech Drug discovery , by Region USD Million (2021-2026)
  • Table 155. AI for Pharma and Biotech Clinical research , by Region USD Million (2021-2026)
  • Table 156. AI for Pharma and Biotech Disease diagnosis , by Region USD Million (2021-2026)
  • Table 157. AI for Pharma and Biotech Novel medication , by Region USD Million (2021-2026)
  • Table 158. AI for Pharma and Biotech Prediction , by Region USD Million (2021-2026)
  • Table 159. AI for Pharma and Biotech Data analysis , by Region USD Million (2021-2026)
  • Table 160. AI for Pharma and Biotech Other , by Region USD Million (2021-2026)
  • Table 161. AI for Pharma and Biotech: by Component(USD Million)
  • Table 162. AI for Pharma and Biotech Software , by Region USD Million (2021-2026)
  • Table 163. AI for Pharma and Biotech Services , by Region USD Million (2021-2026)
  • Table 164. South America AI for Pharma and Biotech, by Country USD Million (2021-2026)
  • Table 165. South America AI for Pharma and Biotech, by Type USD Million (2021-2026)
  • Table 166. South America AI for Pharma and Biotech, by Application USD Million (2021-2026)
  • Table 167. South America AI for Pharma and Biotech, by End Use USD Million (2021-2026)
  • Table 168. South America AI for Pharma and Biotech, by Component USD Million (2021-2026)
  • Table 169. Brazil AI for Pharma and Biotech, by Type USD Million (2021-2026)
  • Table 170. Brazil AI for Pharma and Biotech, by Application USD Million (2021-2026)
  • Table 171. Brazil AI for Pharma and Biotech, by End Use USD Million (2021-2026)
  • Table 172. Brazil AI for Pharma and Biotech, by Component USD Million (2021-2026)
  • Table 173. Argentina AI for Pharma and Biotech, by Type USD Million (2021-2026)
  • Table 174. Argentina AI for Pharma and Biotech, by Application USD Million (2021-2026)
  • Table 175. Argentina AI for Pharma and Biotech, by End Use USD Million (2021-2026)
  • Table 176. Argentina AI for Pharma and Biotech, by Component USD Million (2021-2026)
  • Table 177. Rest of South America AI for Pharma and Biotech, by Type USD Million (2021-2026)
  • Table 178. Rest of South America AI for Pharma and Biotech, by Application USD Million (2021-2026)
  • Table 179. Rest of South America AI for Pharma and Biotech, by End Use USD Million (2021-2026)
  • Table 180. Rest of South America AI for Pharma and Biotech, by Component USD Million (2021-2026)
  • Table 181. Asia Pacific AI for Pharma and Biotech, by Country USD Million (2021-2026)
  • Table 182. Asia Pacific AI for Pharma and Biotech, by Type USD Million (2021-2026)
  • Table 183. Asia Pacific AI for Pharma and Biotech, by Application USD Million (2021-2026)
  • Table 184. Asia Pacific AI for Pharma and Biotech, by End Use USD Million (2021-2026)
  • Table 185. Asia Pacific AI for Pharma and Biotech, by Component USD Million (2021-2026)
  • Table 186. China AI for Pharma and Biotech, by Type USD Million (2021-2026)
  • Table 187. China AI for Pharma and Biotech, by Application USD Million (2021-2026)
  • Table 188. China AI for Pharma and Biotech, by End Use USD Million (2021-2026)
  • Table 189. China AI for Pharma and Biotech, by Component USD Million (2021-2026)
  • Table 190. Japan AI for Pharma and Biotech, by Type USD Million (2021-2026)
  • Table 191. Japan AI for Pharma and Biotech, by Application USD Million (2021-2026)
  • Table 192. Japan AI for Pharma and Biotech, by End Use USD Million (2021-2026)
  • Table 193. Japan AI for Pharma and Biotech, by Component USD Million (2021-2026)
  • Table 194. India AI for Pharma and Biotech, by Type USD Million (2021-2026)
  • Table 195. India AI for Pharma and Biotech, by Application USD Million (2021-2026)
  • Table 196. India AI for Pharma and Biotech, by End Use USD Million (2021-2026)
  • Table 197. India AI for Pharma and Biotech, by Component USD Million (2021-2026)
  • Table 198. South Korea AI for Pharma and Biotech, by Type USD Million (2021-2026)
  • Table 199. South Korea AI for Pharma and Biotech, by Application USD Million (2021-2026)
  • Table 200. South Korea AI for Pharma and Biotech, by End Use USD Million (2021-2026)
  • Table 201. South Korea AI for Pharma and Biotech, by Component USD Million (2021-2026)
  • Table 202. Taiwan AI for Pharma and Biotech, by Type USD Million (2021-2026)
  • Table 203. Taiwan AI for Pharma and Biotech, by Application USD Million (2021-2026)
  • Table 204. Taiwan AI for Pharma and Biotech, by End Use USD Million (2021-2026)
  • Table 205. Taiwan AI for Pharma and Biotech, by Component USD Million (2021-2026)
  • Table 206. Australia AI for Pharma and Biotech, by Type USD Million (2021-2026)
  • Table 207. Australia AI for Pharma and Biotech, by Application USD Million (2021-2026)
  • Table 208. Australia AI for Pharma and Biotech, by End Use USD Million (2021-2026)
  • Table 209. Australia AI for Pharma and Biotech, by Component USD Million (2021-2026)
  • Table 210. Rest of Asia-Pacific AI for Pharma and Biotech, by Type USD Million (2021-2026)
  • Table 211. Rest of Asia-Pacific AI for Pharma and Biotech, by Application USD Million (2021-2026)
  • Table 212. Rest of Asia-Pacific AI for Pharma and Biotech, by End Use USD Million (2021-2026)
  • Table 213. Rest of Asia-Pacific AI for Pharma and Biotech, by Component USD Million (2021-2026)
  • Table 214. Europe AI for Pharma and Biotech, by Country USD Million (2021-2026)
  • Table 215. Europe AI for Pharma and Biotech, by Type USD Million (2021-2026)
  • Table 216. Europe AI for Pharma and Biotech, by Application USD Million (2021-2026)
  • Table 217. Europe AI for Pharma and Biotech, by End Use USD Million (2021-2026)
  • Table 218. Europe AI for Pharma and Biotech, by Component USD Million (2021-2026)
  • Table 219. Germany AI for Pharma and Biotech, by Type USD Million (2021-2026)
  • Table 220. Germany AI for Pharma and Biotech, by Application USD Million (2021-2026)
  • Table 221. Germany AI for Pharma and Biotech, by End Use USD Million (2021-2026)
  • Table 222. Germany AI for Pharma and Biotech, by Component USD Million (2021-2026)
  • Table 223. France AI for Pharma and Biotech, by Type USD Million (2021-2026)
  • Table 224. France AI for Pharma and Biotech, by Application USD Million (2021-2026)
  • Table 225. France AI for Pharma and Biotech, by End Use USD Million (2021-2026)
  • Table 226. France AI for Pharma and Biotech, by Component USD Million (2021-2026)
  • Table 227. Italy AI for Pharma and Biotech, by Type USD Million (2021-2026)
  • Table 228. Italy AI for Pharma and Biotech, by Application USD Million (2021-2026)
  • Table 229. Italy AI for Pharma and Biotech, by End Use USD Million (2021-2026)
  • Table 230. Italy AI for Pharma and Biotech, by Component USD Million (2021-2026)
  • Table 231. United Kingdom AI for Pharma and Biotech, by Type USD Million (2021-2026)
  • Table 232. United Kingdom AI for Pharma and Biotech, by Application USD Million (2021-2026)
  • Table 233. United Kingdom AI for Pharma and Biotech, by End Use USD Million (2021-2026)
  • Table 234. United Kingdom AI for Pharma and Biotech, by Component USD Million (2021-2026)
  • Table 235. Netherlands AI for Pharma and Biotech, by Type USD Million (2021-2026)
  • Table 236. Netherlands AI for Pharma and Biotech, by Application USD Million (2021-2026)
  • Table 237. Netherlands AI for Pharma and Biotech, by End Use USD Million (2021-2026)
  • Table 238. Netherlands AI for Pharma and Biotech, by Component USD Million (2021-2026)
  • Table 239. Rest of Europe AI for Pharma and Biotech, by Type USD Million (2021-2026)
  • Table 240. Rest of Europe AI for Pharma and Biotech, by Application USD Million (2021-2026)
  • Table 241. Rest of Europe AI for Pharma and Biotech, by End Use USD Million (2021-2026)
  • Table 242. Rest of Europe AI for Pharma and Biotech, by Component USD Million (2021-2026)
  • Table 243. MEA AI for Pharma and Biotech, by Country USD Million (2021-2026)
  • Table 244. MEA AI for Pharma and Biotech, by Type USD Million (2021-2026)
  • Table 245. MEA AI for Pharma and Biotech, by Application USD Million (2021-2026)
  • Table 246. MEA AI for Pharma and Biotech, by End Use USD Million (2021-2026)
  • Table 247. MEA AI for Pharma and Biotech, by Component USD Million (2021-2026)
  • Table 248. Middle East AI for Pharma and Biotech, by Type USD Million (2021-2026)
  • Table 249. Middle East AI for Pharma and Biotech, by Application USD Million (2021-2026)
  • Table 250. Middle East AI for Pharma and Biotech, by End Use USD Million (2021-2026)
  • Table 251. Middle East AI for Pharma and Biotech, by Component USD Million (2021-2026)
  • Table 252. Africa AI for Pharma and Biotech, by Type USD Million (2021-2026)
  • Table 253. Africa AI for Pharma and Biotech, by Application USD Million (2021-2026)
  • Table 254. Africa AI for Pharma and Biotech, by End Use USD Million (2021-2026)
  • Table 255. Africa AI for Pharma and Biotech, by Component USD Million (2021-2026)
  • Table 256. North America AI for Pharma and Biotech, by Country USD Million (2021-2026)
  • Table 257. North America AI for Pharma and Biotech, by Type USD Million (2021-2026)
  • Table 258. North America AI for Pharma and Biotech, by Application USD Million (2021-2026)
  • Table 259. North America AI for Pharma and Biotech, by End Use USD Million (2021-2026)
  • Table 260. North America AI for Pharma and Biotech, by Component USD Million (2021-2026)
  • Table 261. United States AI for Pharma and Biotech, by Type USD Million (2021-2026)
  • Table 262. United States AI for Pharma and Biotech, by Application USD Million (2021-2026)
  • Table 263. United States AI for Pharma and Biotech, by End Use USD Million (2021-2026)
  • Table 264. United States AI for Pharma and Biotech, by Component USD Million (2021-2026)
  • Table 265. Canada AI for Pharma and Biotech, by Type USD Million (2021-2026)
  • Table 266. Canada AI for Pharma and Biotech, by Application USD Million (2021-2026)
  • Table 267. Canada AI for Pharma and Biotech, by End Use USD Million (2021-2026)
  • Table 268. Canada AI for Pharma and Biotech, by Component USD Million (2021-2026)
  • Table 269. Mexico AI for Pharma and Biotech, by Type USD Million (2021-2026)
  • Table 270. Mexico AI for Pharma and Biotech, by Application USD Million (2021-2026)
  • Table 271. Mexico AI for Pharma and Biotech, by End Use USD Million (2021-2026)
  • Table 272. Mexico AI for Pharma and Biotech, by Component USD Million (2021-2026)
  • Table 273. AI for Pharma and Biotech: by Type(USD/Units)
  • Table 274. Research Programs/Design for This Report
  • Table 275. Key Data Information from Secondary Sources
  • Table 276. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global AI for Pharma and Biotech: by Type USD Million (2015-2020)
  • Figure 5. Global AI for Pharma and Biotech: by Application USD Million (2015-2020)
  • Figure 6. Global AI for Pharma and Biotech: by End Use USD Million (2015-2020)
  • Figure 7. Global AI for Pharma and Biotech: by Component USD Million (2015-2020)
  • Figure 8. South America AI for Pharma and Biotech Share (%), by Country
  • Figure 9. Asia Pacific AI for Pharma and Biotech Share (%), by Country
  • Figure 10. Europe AI for Pharma and Biotech Share (%), by Country
  • Figure 11. MEA AI for Pharma and Biotech Share (%), by Country
  • Figure 12. North America AI for Pharma and Biotech Share (%), by Country
  • Figure 13. Global AI for Pharma and Biotech: by Type USD/Units (2015-2020)
  • Figure 14. Global AI for Pharma and Biotech share by Players 2020 (%)
  • Figure 15. Global AI for Pharma and Biotech share by Players (Top 3) 2020(%)
  • Figure 16. Global AI for Pharma and Biotech share by Players (Top 5) 2020(%)
  • Figure 17. BCG Matrix for key Companies
  • Figure 18. CureMetrix (United States) Revenue, Net Income and Gross profit
  • Figure 19. CureMetrix (United States) Revenue: by Geography 2020
  • Figure 20. PFIZER (United States) Revenue, Net Income and Gross profit
  • Figure 21. PFIZER (United States) Revenue: by Geography 2020
  • Figure 22. Abbott (United States) Revenue, Net Income and Gross profit
  • Figure 23. Abbott (United States) Revenue: by Geography 2020
  • Figure 24. JANSSEN PHARMACEUTICALS (Belgium) Revenue, Net Income and Gross profit
  • Figure 25. JANSSEN PHARMACEUTICALS (Belgium) Revenue: by Geography 2020
  • Figure 26. SANOFI (France) Revenue, Net Income and Gross profit
  • Figure 27. SANOFI (France) Revenue: by Geography 2020
  • Figure 28. NOVARTIS (Switzerland) Revenue, Net Income and Gross profit
  • Figure 29. NOVARTIS (Switzerland) Revenue: by Geography 2020
  • Figure 30. VoxelCloud (United States) Revenue, Net Income and Gross profit
  • Figure 31. VoxelCloud (United States) Revenue: by Geography 2020
  • Figure 32. BAYER (Germany) Revenue, Net Income and Gross profit
  • Figure 33. BAYER (Germany) Revenue: by Geography 2020
  • Figure 34. Insilico Medicine (Hong Kong) Revenue, Net Income and Gross profit
  • Figure 35. Insilico Medicine (Hong Kong) Revenue: by Geography 2020
  • Figure 36. Oncora Medical (United States) Revenue, Net Income and Gross profit
  • Figure 37. Oncora Medical (United States) Revenue: by Geography 2020
  • Figure 38. Atomwise (United States) Revenue, Net Income and Gross profit
  • Figure 39. Atomwise (United States) Revenue: by Geography 2020
  • Figure 40. Global AI for Pharma and Biotech: by Type USD Million (2021-2026)
  • Figure 41. Global AI for Pharma and Biotech: by Application USD Million (2021-2026)
  • Figure 42. Global AI for Pharma and Biotech: by End Use USD Million (2021-2026)
  • Figure 43. Global AI for Pharma and Biotech: by Component USD Million (2021-2026)
  • Figure 44. South America AI for Pharma and Biotech Share (%), by Country
  • Figure 45. Asia Pacific AI for Pharma and Biotech Share (%), by Country
  • Figure 46. Europe AI for Pharma and Biotech Share (%), by Country
  • Figure 47. MEA AI for Pharma and Biotech Share (%), by Country
  • Figure 48. North America AI for Pharma and Biotech Share (%), by Country
  • Figure 49. Global AI for Pharma and Biotech: by Type USD/Units (2021-2026)
Some of the key companies/manufacturers profiled in the report
  • CureMetrix (United States)
  • PFIZER (United States)
  • Abbott (United States)
  • JANSSEN PHARMACEUTICALS (Belgium)
  • SANOFI (France)
  • NOVARTIS (Switzerland)
  • VoxelCloud (United States)
  • BAYER (Germany)
  • Insilico Medicine (Hong Kong)
  • Oncora Medical (United States)
  • Atomwise (United States)
Additional players considered in the study are as follows:
Aria Pharmaceuticals (United States) , Berg Health (United States) , CloudMedX (United States) , Deep Genomics (Canada)
Select License Type
Sample Report Enquiry Before Buy Request Discount

Speak with Analyst

Want to find out more about this report?

Get Free Consultation